| Mobile Web

Search results for Massachusetts

AI & Enterprise

Fully AI-designed new drugs are only a matter of time, AstraZeneca blueprint shows

Artificial intelligence is becoming core infrastructure in biopharmaceutical development, rapidly changing how drug candidates are found and validated. AstraZeneca says computing now reinforces the entire process from design and production to verification and analysis, shortening development cycles and boosting productivity. The company uses a build-measure-learn loop, multimodal datasets and precision screening, and is building an AI- and robot-enabled lab in Cambridge, Massachusetts. Executives say de novo, fully AI-generated biologics are an industry goal but require richer data, benchmarks and talent, with human oversight remaining central.

Industry

MIT finds clue to key hurdle in all-solid-state batteries

A study found that a key cause of short circuits in all-solid-state batteries lies in grain boundaries inside solid electrolytes. Researchers from the Massachusetts Institute of Technology and the Technical University of Munich identified a main driver of lithium-metal dendrite growth and proposed a process solution to reduce it. Using AI and analysis methods, they tracked current flow and adjusted electrolyte processing to cut damage and energy loss. They said current density rose by more than 300 percent in tests.